Company Updates
News
Breath Biopsy
Owlstone Medical Introduces Breath Biopsy Panel for Respiratory Diseases
Panel supports research to distinguish between types of chronic inflammatory airway disease including Asthma, COPD and IPF Enables direct characterization of disease biology by non-invasively sampling the airways First commercial launch from pipeline of Breath Biopsy RUO Panel and IVD tests Cambridge, UK, January 19, 2021: Owlstone Medical, the global leader in ...
Breath Biopsy
Owlstone Medical Announces Key Study Results on use of Breath Biopsy for Improved Detection of Liver Disease including NASH and NAFLD
Breath Biopsy
DRAGON: A new international project funded by IMI and supported through the European Commission’s Horizon 2020 Framework Programme for Research and Innovation to develop a diagnostics tool combatting coronavirus infections.
Company Updates
Owlstone Medical Appoints Neil Tween as Chief Financial Officer
Company Updates
Owlstone Medical named as one of FierceMedTech’s “Fierce 15” companies of 2019
Breath Biopsy
Owlstone Medical to Join EU-Funded EPHOR Consortium to Advance Occupational Health Science in Order to Reduce Disease Burden from Workplace Exposure
Breath Biopsy
Owlstone Medical Enters Partnership with Thermo Fisher Scientific to Advance Early Disease Detection Using Non-Invasive Breath Biopsy
Breath Biopsy
Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases
Breath Biopsy
Cleveland Clinic Partners with Owlstone Medical to Establish New Center
Breath Biopsy
Owlstone Medical Announces Advancements in Breath Biopsy Platform Including Launch of Next Generation ReCIVA Breath Sampler and CASPER Portable Air Supply
Breath Biopsy
Owlstone Medical Announces a Novel Approach to Breath-Based Testing for Investigation of the Onset, Progression, and Treatment of Disease
Breath Biopsy
Owlstone Medical and the International Association of Heat and Frost Insulators and Allied Workers Partner to Identify Breath Biomarkers for the Early Detection of Malignant Mesothelioma
